liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012
Karolinska Institute, Sweden; Karolinska University Hospital, Sweden.
Karolinska Institute, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Cardiology in Linköping.ORCID iD: 0000-0001-6353-8041
Karolinska Institute, Sweden.
Show others and affiliations
2016 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 18, no 5, 503-511 p.Article in journal (Refereed) PublishedText
Abstract [en]

Aims In heart failure with reduced ejection fraction, drug and device therapy improve survival. We studied contemporary trends in utilization of evidence-based therapy and associated survival. Methods and results We studied 5908 patients with NYHA class II-IV heart failure, EF amp;lt;30%, and duration of heart failure amp;gt;= 6 months registered in the Swedish Heart Failure Registry between 2003 and 2012. Regression using generalized estimation equations was used to examine temporal trends in crude and risk-adjusted rates of utilization of evidence-based heart failure therapy and 30-day, 1-year, and 3-year survival. In 2003 vs. 2012, the risk-adjusted use of therapy and P-values for trends were as follows: renin-angiotensin system antagonists, 88% vs. 86% (P = 0.091); beta-blockers, 85% vs. 93% (P = 0.008); mineralocorticoid receptor antagonists, 53% vs. 42% (P amp;lt; 0.001); CRT, 2.4% vs. 8.2% (P = 0.074); and implantable cardioverter-defibrillators, 4.0% vs. 10.7% (P = 0.004). During the same period, the risk-adjusted 30-day, 1-year, and 3-year survival was 92% vs. 94% (P = 0.532), 81% vs. 77% (P = 0.260), and 58% vs. 54% (P = 0.425), respectively. Conclusions In this large nationwide registry, over the last decade the use of evidence-based drug therapy was high and remained stable over time, but, despite an increased use of device therapy, the absolute use was poor. This was associated with an absence of improvement in survival. The improvements in therapy and prognosis over the last generation may be levelling off, and efforts should be directed at improving implementation of evidence-based therapy.

Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2016. Vol. 18, no 5, 503-511 p.
Keyword [en]
Heart failure; Evidence-based therapy; Guidelines; Utilization; Implementation; Outcomes
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:liu:diva-130443DOI: 10.1002/ejhf.496ISI: 000379258400010PubMedID: 26869252OAI: oai:DiVA.org:liu-130443DiVA: diva2:951155
Available from: 2016-08-06 Created: 2016-08-05 Last updated: 2016-08-06

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Cardiology in Linköping
In the same journal
European Journal of Heart Failure
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 6 hits
ReferencesLink to record
Permanent link

Direct link